US
If visiting the DiaSorin Site from a region that doesn't coincide with your location, some products may not be available. This is due to regulatory requirements and restrictions.
24/04/24 - 15:38
Shareholders' Meeting 2024 (159.72 KB)
Other
16/04/24 - 8:20
Communication on total amount of voting rights (135.47 KB)
Other
04/04/24 - 9:34
DiaSorin S.p.A.- Update 2024 Annual Calendar of Corporate Events (103.76 KB)
Financial Disclosures
,
Other
15/03/24 - 17:14
Diasorin: Publication of the documents for the Ordinary Shareholders' Meeting scheduled on April 24, 2024 (135.35 KB)
Other
15/03/24 - 13:35
The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
Financial Data
13/03/24 - 10:23
Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)
Products
Molecular
03/03/24 - 19:32
Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)
Products
Molecular
25/01/24 - 7:48
Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)
Products
Immunodiagnostic
18/01/24 - 12:30
2024 Annual Calendar of Corporate Events (115.8 KB)
Other